Multiple Strategies to Develop Small Molecular KRAS Directly Bound Inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• KRAS gene mutations are prevalent in numerous cancers, driving tumor development and progression.
• Targeting KRAS mutations represents a significant challenge and a primary objective in modern cancer therapy.
• Developing direct KRAS inhibitors is essential for advancing targeted anti-cancer treatments.

Purpose of the Study:

• To summarize the diverse strategies employed in developing direct KRAS inhibitors.
• To provide an overview of the current landscape of KRAS-directed therapies.
• To highlight the implications of these strategies for future drug discovery targeting KRAS and other challenging proteins.

Main Methods:

• Review and synthesis of recent advancements in KRAS inhibitor development strategies.
• Categorization of therapeutic approaches including covalent binding, protein degradation, and protein-protein interaction inhibition.
• Analysis of specific KRAS inhibitors, including FDA-approved drugs and investigational agents.

Main Results:

• Multiple innovative strategies are being utilized to develop direct KRAS inhibitors.
• Several KRAS inhibitors, such as sotorasib, adagrasib, MRTX1133, and JAB-23000, have been developed.
• These strategies have significantly accelerated the progress in KRAS inhibitor drug discovery.

Conclusions:

• The diverse strategies discussed are pivotal in advancing the development of KRAS inhibitors.
• This summary offers insights into overcoming challenges in targeting KRAS mutations for cancer therapy.
• The approaches may guide the discovery of drugs for other previously undruggable targets.